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HELICOBACTER PYLORI
Aspirin inhibits the growth of Helicobacter pylori and
enhances its susceptibility to antimicrobial agents
W H Wang, W M Wong, D Dailidiene, D E Berg, Q Gu, K C Lai, S K Lam, B C Y Wong
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Gut 2003;52:490–495
Background and aim: The role of Helicobacter pylori and aspirin in peptic ulcer formation and
recurrence remains an important clinical topic. The interaction between aspirin and H pylori in vitro is
also not clear. We investigated the effect of aspirin on the growth of H pylori and on the susceptibility
of H pylori to antimicrobials.
Methods: Time killing studies of H pylori were performed with different concentrations of aspirin and
salicylate. Growth of bacteria was assessed spectrophotometrically and by viable colony count. The
effects of aspirin on the efficiency of colony formation and on metronidazole induced mutation to
rifampicin resistance in H pylori were determined. Minimal inhibitory concentrations (MICs) of aspirin
and metronidazole were tested by the standard agar dilution method. MICs of amoxycillin and clari-
thromycin were determined by the E test method.
Results: Aspirin and salicylate inhibited the growth of H pylori in a dose dependent manner and bac-
tericidal activity was due to cell lysis. Aspirin 400 µg/ml caused a 2 logs decrease in colony forming
units/ml at 48 hours, and suppressed the normal ability of metronidazole to induce new mutations to
rifampicin. The IC90 of aspirin was 512 µg/ml. Increased susceptibility of amoxycillin, clarithromycin,
and metronidazole to H pylori was observed at 1 mM (180 µg/ml) aspirin.
Conclusions: Aspirin inhibited the growth of H pylori, suppressed the mutagenic effect of metronida-
zole, and enhanced the susceptibility of H pylori to antimicrobial agents. This mechanism is important
in future drug development for effective clearing and overcoming resistance.
Helicobacter pylori and aspirin are the two most importantcausative factors in the pathogenesis of peptic ulcer.However, themechanism of interaction betweenH pylori
and aspirin has not been sufficiently documented to date,
either in vitro or in vivo. In one study, the number of
endoscopic mucosal lesions in patients taking low dose aspirin
was higher in those with H pylori infection than in those with
no H pylori infection.1 In another study, more antral ulcers
occurred in H pylori negative than in H pylori positive subjects
taking low dose aspirin.2 It is generally recognised thatH pylori
infection does not worsen mucosal injury with aspirin or non-
steroidal anti-inflammatory drug (NSAID) usage because H
pylori infection is associated with increased mucosal levels of
prostaglandins.2–4 Although reports from clinical studies are
controversial,1 2 5 it seems that there is no meaningful
difference in H pylori prevalence between aspirin users and
non-users.6 7 The background rate of infection in aspirin or
NSAID users was high, ranging from 24% to 68%, but therapy
with aspirin or NSAIDs does not increase susceptibility to H
pylori infection.5–7
Previous studies have reported that aspirin and other
NSAIDs interfere with growth of both Gram negative and
Gram positive bacteria in vitro, such as Escherichia coli,8 9 Can-
dida albicans,8 9 Staphylococcus saprophyticus,8 9 Pseudomonas cepa-
cia, 10 11 and Staphylococcus aureus.12 In some organisms,
increased resistance or susceptibility to several antibiotics can
be induced by growing in a subinhibitory concentration of
aspirin.10–14 Graham and colleagues15 reported that H pyloriwas
not susceptible to aspirin and other NSAIDs, such as
indomethacin, ibuprofen, naproxen, or tolmetin in vivo. How-
ever, Caselli and colleagues5 observed an anti-H pylori effect of
aspirin, diclofenac, and ketoprofen in vitro. Therefore, we
undertook this study to evaluate the possible effect of aspirin
on the growth of H pylori and further determined the effect of
this drug on susceptibility of H pylori to antimicrobial agents.
MATERIAL AND METHODS
Bacterial strains
The experiments were conducted with 63 clinical isolates of H
pylori from ethnic Chinese in Hong Kong, reference strains
NCTC 11637, NCTC 12908, and isogenic metronidazole
susceptible (MtzS) and resistance (MtzR) derivatives of H
pylori 26695, containing rdxA::cam and frxA::kan single and
double knockout mutations in the nitroreductase genes, and
equivalent derivatives of SS1. The clinical isolates were
obtained from patients undergoing upper endoscopy exam-
ination and were maintained frozen at −80°C in brain heart
infusion (BHI) broth (BHI; Oxoid, Basingstoke, UK) with 20%
glycerol. Endoscopic diagnosis included normal appearing
mucosa in 15 patients, duodenal ulcer in 30 patients, gastric
ulcer in three patients, and gastric cancer in five patients. An
additional eight H pylori isolates from aspirin taking patients
and two isolates from other NSAID taking patients were
included in the study. Bacteria were re-plated on Columbia
agar (Oxoid) supplemented with 7% horse blood under
microaerobic conditions produced by a gas generating system
(CampyGen; Oxoid) for three days. A non-pathogenic E coli
strain (DH5a) was also included and cultured under similar
conditions as described above in an aerobic ambient.
Chemicals
Aspirin (Sigma Chemical Co, St Louis, USA) was freshly
dissolved in dimethylsulphoxide (DMSO; Sigma, USA) and
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metronidazole (Fluka, Switzerland) was prepared in water.
Sodium salicylate (Sigma Chemical Co) was dissolved in
water.
Establishment of growth in broth medium
Time killing studies were performed using five different
strains (NCTC 11637, NCTC 12908, 26695, one isolate from a
duodenal ulcer patient, and one isolate from a gastric ulcer
patient) in Brucella broth (Difco Laboratories, Detroit, Michi-
gan, USA) supplemented with 10% fetal bovine serum (FBS;
Gibco-BRL, Grand Island, New York, USA). Culture media (20
ml) in a set of 10 cm petri dishes with or without test drug
were inoculated with 108 colony forming units (CFU)/ml of H
pylori. Dishes were placed in an anaerobic jar (Oxoid) and
incubated at 37°C under microaerobic conditions, as described
above, on a shaker at 90 rpm. A vehicle control of DMSO (less
than 0.1%) was included in the studies.
Determination and adjustment of pH
The pH of Brucella broth supplemented with 10% FBS before
inoculation with or without aspirin was measured using a
digital pH meter (HI 9024; Hanna Instrument, Portugal).
Growth of H pylori NCTC 11637 in the presence of aspirin (400
µg/ml) was compared with that in the medium with the same
pH adjusted by 1 N HCl in the absence of the drug.
Growth measurement
Growth of bacteria in broth was assessed spectrophotometri-
cally at 600 nm and by viable colony count. At 24 and 48 hours,
samples were removed and serially diluted 10-fold, and colony
counts were determined by plating 100 µl of each dilution on
duplicate agar plates that allow optimal growth of H pylori.
After 4–6 days of incubation under microaerobic conditions at
37°C, the plates were read.
Microscopy
Undiluted samples from the above broth medium with either
aspirin or vehicle, after incubation for 24 and 48 hours, were
spread onto glass slides and examined under Gram stain by
light microscopy.
Determination of efficiency of plating
Strains of H pylori were inoculated on Columbia blood agar
plates with various concentrations of aspirin (0, 100, 200
µg/ml) and metronidazole (0, 3, 8, 16, 25, 32 µg/ml), and were
incubated under microaerobic conditions at 37°C for three
days. Wild-type and isogenic MtzS and MtzR derivatives of
strain 26695, and rdxA::cam and frxA::kan single and double
knockout mutant derivatives of strains 26695 and SS1 were
included in this study to test the possible effects on aspirin
sensitivity of loss of nitroreductases encoded by rdxA and
frxA, the activities responsible for susceptibility of H pylori to
metronidazole.16 The efficiency of plating was the titre of CFU
obtained from the plates with the test drug divided by the titre
obtained from the control plates without drug.
Metronidazole induced mutation
New mutations to rifampicin resistance (RifR), which result
from changes in the rpoB gene,17 were quantified as a measure
of metronidazole induced mutation in H pylori. Bacterial cells
(107–108) of isogenic MtzS and MtzR derivative of 26695 were
spread onto Columbia agar plates containing various concen-
trations of metronidazole (0, 3, 8, 16, 25, 32 µg/ml) and aspi-
rin (0, 100, 200 µg/ml). Following three days of incubation,
bacterial cells were suspended in phosphate buffered saline
and spread on Columbia blood agar with 5 µg/ml rifampicin,
and titrated by spotting aliquots of serial 10-fold dilutions on
rifampicin free medium. Each test was repeated three times
and average values were reported.
MIC determination
Bacteria were prepared in BHI to yield a viable count of 3×108
CFU/ml (equivalent to 1 McFarland turbidity standard unit),
and used as the inoculum for susceptibility testing. The mini-
mal inhibitory concentrations (MICs) of aspirin were deter-
mined by the agar dilution method according to NCCLS docu-
ment M11-A2 on 66 strains of H pylori,18 and the MICs of other
antimicrobials (clarithromycin and amoxycillin) were deter-
mined by the E test method, according to the manufacturer’s
guidelines, on 24 strains (including three reference strains).
MIC was recorded as the lowest concentration that inhibited
visible growth of organisms and the results were determined
after 72 hours of incubation at 37°C under microaerobic con-
ditions.
For the agar dilution method, aspirin or metronidazole was
diluted in distilled water and incorporated separately into
Columbia blood agar. Plates contained twofold serial dilutions
of drugs from 8 to 1024 µg/ml. Each bacterial suspension (1
µl) was inoculated (3×105 CFU/spot) on drug containing
plates. Plates with no drugs were inoculated at the beginning
and end of each run as controls.
To determine the possible effect of aspirin on the MICs of
amoxycillin, metronidazole, and clarithromycin, susceptibility
testing of these three widely used antimicrobials in the pres-
ence or absence of aspirin were performed using the E test and
agar dilution methods. Aspirin at a final concentration of 1
mM (180 µg/ml) was added to Columbia blood agar to obtain
aspirin containing plates. Each bacterial suspension (100 µl)
was spread on plates with or without aspirin using a cotton
swab. A single E test drug strip (AB Biodisk, Sweden) was
applied to the surface of each dried plate. For each strain,
MICs obtained in the presence or absence of aspirin were
compared. E coli (DH5a) was included in this assay.
Statistical analysis
Time killing studies of H pylori were performed using five dif-
ferent strains. Representative data from these experiments are
presented as mean (SEM). The Student’s t test was used to
compare data. A p value of less than 0.05 was considered sta-
tistically significant.
RESULTS
Effects of aspirin and salicylate on the growth of
H pylori
Strains of H pylori were inoculated in broth medium contain-
ing various concentrations of aspirin (0, 200, 300, and 400
µg/ml) and salicylate (0, 0.56, 1.1, 1.6, and 2.2 mM). The
effects on the growth of bacteria were determined spectropho-
tometrically as well as by a viable count method at 0, 24, and
48 hours. Similar results were obtained by performing experi-
ments with five different strains, indicating that aspirin
inhibited the growth of H pylori in a dose dependent manner.
As determined by optical density at 600 nm, aspirin at a con-
centration of 100 µg/ml began to show an inhibitory effect on
the growth of H pylori compared with the vehicle control. Con-
centration of aspirin of 400 µg/ml stopped increases in optical
density, indicating cessation of cell growth. Further tests,
based on determining the numbers of bacteria that could form
colonies, showed that aspirin at a concentration of 400 µg/ml
was lethal, resulting in a 1 log reduction in the numbers of
CFU/ml relative to the numbers in the inoculum at 24 hours,
and produced nearly a 2 log decrease at 48 hours (fig 1A). The
experiment was repeated using equivalent concentration of
salicylate and the results were essentially similar to those of
aspirin (fig 1B). Morphological studies performed by Gram
staining revealed complete lysis of cells incubated with 400
µg/ml of aspirin for 48 hours whereas no such lysis was
detected in control cultures (fig 2). No significant coccoid for-
mation was found after aspirin treatment.
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Effects of decreased pH on the growth of H pylori
The pH of Brucella broth supplemented with 10% FBS before
inoculation was 7.26 whereas the pH of the medium after
adding 400 µg/ml of aspirin was 6.90. However, growth of H
pylori NCTC 11637 in the presence of 400 µg/ml aspirin was
2 logs lower than that in the absence of the drug at the same
pH after 48 hours of incubation (fig 1C). Thus aspirin does not
exert its effect by changing the pH of the medium.
Synergism between metronidazole and aspirin
Adding aspirin to Columbia blood agar medium caused
marked decreases in colony size compared with controls. No
rdxA or frxA dependent differences in efficiency of plating or
colony size as a function of aspirin dose were detected. The
efficiency of plating decreased more dramatically with doses
of 16, 25, or 32 µg/ml of metronidazole with aspirin 100 µg/ml,
and especially with aspirin 200 µg/ml, compared with aspirin
free plates. Thus aspirin and metronidazole were strongly syn-
ergistic with respect to inhibition of H pylori colony formation.
Effect of aspirin on metronidazole induced mutation
Inclusion of inhibitory levels of aspirin (100 or 200 µg/ml) in
blood agar medium suppressed the normal ability of metroni-
dazole at 25 or 32 µg/ml to induce new mutations to RifR (fig
3).
MICs of aspirin
The MICs of aspirin for 66 H pylori strains were tested. The
MIC50 of aspirin was 256 µg/ml, MIC90 was 512 µg/ml, and the
range of MIC values was 256–512 µg/ml. There were no differ-
ences regarding MICs against reference strains and clinical
isolates derived from patients taking or not taking aspirin.
MICs of amoxycillin, metronidazole, and clarithromycin
in the presence of aspirin
Susceptibility testing of three widely used antimicrobial
agents (amoxycillin, metronidazole, and clarithromycin) in H
pylori eradication was performed on 24 strains in the presence
of aspirin at a final concentration of 1 mM (180 µg/ml) and
compared with that in the absence of aspirin. Aspirin
decreased MICs in all strains (24/24, 100%) tested for amoxy-
cillin, and 18 strains (18/24, 75%) tested for metronidazole
and clarithromycin, indicating increased susceptibility of H
pylori to these drugs. More log2 decreases in MICs were found
for metronidazole compared with clarithromycin (3.75 (0.77)
v 1.87 (0.46); p=0.04) (fig 4). It was difficult to determine the
exact value of the log2 decrease in MIC for amoxycillin as H
pylori, in the presence or absence of aspirin, was very suscepti-
ble to amoxycillin. For the six resistant strains (four resistant
to metronidazole only, one resistant to both metronidazole
and clarithromycin, and one resistant to clarithromycin only),
Figure 1 Inhibitory effect of aspirin and salicylate on the growth of
Helicobacter pylori. (A) Aspirin treatment; (B) salicylate treatment.
Data are representative of the average of five independent
experiments using different strains. (C) Growth of H pylori strain
NCTC 11637 in the presence (pH dropped from 7.2 to 6.9 after
aspirin) and absence (pH titrated to 6.9 by 1 N HCl) of aspirin. All
results are expressed as the mean (SEM) of at least three
independent experiments. DMSO, dimethylsulphoxide; CFU, colony
forming unit.
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Figure 2 Gram staining of Helicobacter pylori strain NCTC
11637. (A) Vehicle control at 48 hours. (B) Treated with 200 µg/ml
aspirin at 48 hours. (C) Treated with 400 µg/ml aspirin at 48 hours.
Magnifications ×1000.
Figure 3 Inhibitory effect of aspirin on metronidazole induced
mutation to rifampicin resistance (RifR) after three days of incubation
in Columbia agar containing various concentrations of
metronidazole and aspirin. All results are expressed as the mean
(SEM) of three independent experiments .
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MICs decreased significantly in the presence of aspirin (table
1). Aspirin converted five strains from resistant to susceptible.
In contrast, the MICs of these drugs increased in the presence
of aspirin when E coli was used as the testing strain under the
same conditions.
DISCUSSION
Although there is great interest in the role of H pylori infection
and aspirin usage in peptic ulcer diseases, information on the
mechanism of interaction between the two factors is lacking.
H pylori may provide some protection against aspirin related
ulcers due to its ability to stimulate mucosal synthesis of
prostaglandins,2–4 or aspirin may influence the pathogenic
effects of H pylori as a result of possible effects on this micro-
organism. In the present study, we found that aspirin and
salicylate significantly inhibited the growth ofH pylori in vitro,
and reduced the efficiency of colony formation and colony
size. Growth inhibition was found in all strains tested, includ-
ing all clinical isolates, two reference strains (NCTC 11637,
NCTC 12908),H pylori 26695 and SS1, and their isogenic MtzR
derivatives (rdxA::cam and frxA::kan single and double
knockout mutants). This indicates that the inhibitory effect of
aspirin is universal amongH pylori. No rdxA or frxA dependent
differences in efficiency of colony formation or colony size in
relation to aspirin dose were found. The fact that aspirin
inhibited the growth of H pylori was in accordance with previ-
ous studies, which showed that aspirin could inhibit the
growth of other bacterial species.8–12
Some have postulated that the coccoid form is a dormant
stage of H pylori used for survival in hostile environments19–21
whereas others have argued that coccoid forms are simply
dead or dying.22 In any case, no coccoid formation was induced
by the stress of aspirin treatment, not associated with the
lethality of higher doses. There was a tendency for H pylori to
form clusters when treated with aspirin. The reason for this is
uncertain but may be related to changes in membrane proper-
ties (see below).
H pylori can survive in vitro in a wide pH range of 4.0–
8.0.23–27 Aspirin (pKa 3.5) is a weak acid,
28 leading to a pH drop
from 7.26 to 6.90 when added to the medium at 400 µg/ml.
Growth of H pylori was inhibited significantly in the presence
of aspirin compared with controls at the same pH. This
showed that the inhibitory effect of aspirin on the growth ofH
pylori was not solely due to its ability to act as a weak acid.
A plasma level of 20–100 µg/ml of aspirin is recommended
for analgesia and 150–300 µg/ml for an anti-inflammatory
effect.28 Relatively high concentrations of aspirin are used for
pain and fever, and in rheumatic fever, gout, and rheumatoid
arthritis.29 In our study, the inhibitory effect of aspirin on H
pylori was observed at 100 µg/ml and the increasing suscepti-
bility to amoxycillin, clarithromycin, and metronidazole was
induced by aspirin at 1 mM (180 µg/ml). Therefore, the effec-
tive concentrations of aspirin on H pylori in vitro are compar-
able with normal plasma levels. These concentration of aspirin
may be reached only transiently because it is rapidly metabo-
lised to salicylate.We repeated the experiment using salicylate
at a concentration of 0.56, 1.1, 1.6, and 2.2 mM (equivalent to
aspirin 100, 200, 300, and 400 µg/ml, respectively) and the
results were essentially similar (fig 1B). A plasma salicylate
level of 1.4–1.8 mM is considered therapeutic and plasma lev-
els greater than 2.2 mM are potentially toxic in chronic
salicylate dosing. Thus the effect of aspirin and salicylate
demonstrated in our study is achievable in vivo.
Although the mechanism by which aspirin inhibits the
growth of H pylori and increases susceptibility to amoxycillin,
clarithromycin, and metronidazole was not investigated in
this study, the efficiency of plating decreased with high doses
of metronidazole in the presence of aspirin. This apparent
synergism between aspirin and metronidazole reflects in part
the reduction in colony size to the point of invisibility but
might be distinct from outright killing caused by bactericidal
concentrations of metronidazole itself.16
Metronidazole at partially inhibitory concentrations causes
mutation in growingH pylori due to conversion of this prodrug
to hydroxylamine and related compounds that are both bacte-
ricidal and mutagenic. It is remarkable that aspirin treatment
suppressed this normal mutagenic effect of metronidazole on
H pylori even though it exacerbated its lethality. This implies
that these two drugs act in different manners, and suggests
models in which incipient mutant bacteria which have been
weakened by metronidazole exposure may be killed preferen-
tially by aspirin.
We then quantified new mutations to RifR in the presence
or absence of aspirin, as a measure of metronidazole induced
mutation in H pylori. The results showed clearly that inclusion
of inhibitory levels of aspirin suppressed, rather than
enhanced, the normal ability of metronidazole at 25 µg/ml or
32 µg/ml to induce new mutations to RifR. These data suggest
that the inhibitory effect of aspirin on H pylori involves a
mechanism distinct from DNA base modification and prob-
ably strand breakage also, the types of damage that underlie
the mutagenic and bactericidal effects of metronidazole on
this gastric pathogen.30
There has been extensive study of the interaction between
aspirin and various antibiotics in organisms such as E coli.
Aspirin or salicylate increase the resistance of E coli to several
negatively charged or neutral antibiotics, including ampicillin,
tetracycline, chloramphenicol, nalidixic acid, and
cephalosporins.31 32 One mechanism of this resistance entails
aspirin induced downregulation of expression of the outer
membrane porin OmpF,33–35 which serves as a channel for the
entry of these antibiotics into the periplasmic space.36
Figure 4 Log2 decrease in the minimal inhibitory concentration
(MIC) of metronidazole (Met) and clarithromycin (Cla) in the
presence of aspirin in 24 Helicobacter pylori strains. Greater log2
decreases in MICs were found for metronidazole compared with
clarithromycin (3.75 (0.77) v. 1.87 (0.46); p=0.04). Horizontal
bars indicate mean log2 decreases.
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Table 1 Minimal inhibitory concentrations for the six
representative strains in the presence or absence of
aspirin
Metronidazole Clarithromycin
No of
strains No aspirin Aspirin No aspirin Aspirin
1 128 0.25 0.016 0.016
2 256 0.25 128 2
3 64 0.5 0.032 0.016
4 256 0.032 0.064 0.016
5 32 0.016 0.25 0.125
6 4 0.25 16 0.032
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Salicylate decreased the amount of OmpF by two means, one
dependent on and one independent of the much studied mul-
tiple antibiotic resistant gene in E coli.34 35 37 In clinical isolates
this may result from stepwise mutations that may revert when
antibiotic selection pressure is removed. In addition, aspirin is
a weak acid and could increase the membrane potential of
species such as E coli, Salmonella typhimurium, and Pseudomonas
aeruginosa, and thereby enhance the susceptibility to drugs
such as novobiocin and aminoglycoside antibiotics.13 14 Sali-
cylates can also increase the uptake of divalent ions such as
cadmium in E coli, potentiating Cd2+ toxicity, independent of
an increase in membrane potential.38 39 In this study, we
observed increased susceptibility to amoxycillin, clarithromy-
cin, and metronidazole of H pylori in the presence of aspirin.
Whether the above mechanisms are true for H pylori remains
to be determined.
Three results indicate that the increased susceptibility to
amoxycillin, clarithromycin, and metronidazole caused by
aspirin was not solely due to changes in pH in aspirin
containing medium. Firstly, the pH of the Columbia agar
medium decreased from 7.20 to 7.08 with 1 mM aspirin, and
thus this pH change did not interfere significantly with the
growth of H pylori.40 Secondly, the bactericidal activity of
amoxycillin and clarithromycin require high growth rate and
high expression of bacterial targets at neutral pH, and
increased resistance to these antibiotics will be observed for
the poor growth or non-dividing state of bacteria at acidic
pH.24 41 42 Thirdly, metronidazole, a DNA targeted antibiotic,
does not depend on bacterial cell division for its activity.
Therefore, the activity of metronidazole is not pH dependent
and remains stable.24 41 43 This was in accordance with our
finding that the log2 decrease in MIC of metronidazole was
more frequently observed than that of amoxycillin and
clarithromycin in the presence of aspirin.
In conclusion, our results provide evidence that aspirin
inhibits the growth of H pylori and increases the susceptibility
to antimicrobial agents in vitro. How well this in vitro activity
translates to in vivo effectiveness either in clearing the infec-
tion or in suppressing metronidazole induced mutation (that
may be important in virulence or drug resistance) merits fur-
ther analysis in clinical and experimental animal infection
studies. This mechanism is therefore important in future drug
development for effective clearing and overcoming resistance.
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